ysbiopharm.com (LSB) Short-Term Debt to Equity
The financial price action for LakeShore Biopharma Co. (LSB) demonstrates a debt-to-equity ratio of 0.00. The Chinese leader in anti-rabies drug development relies on Asian medical networks and the advancement of mRNA technologies. Despite stringent oversight from US regulators, local production protects the core asset. Simultaneously, LakeShore Biopharma Co. (LSB) is implementing ESG standards, reducing its carbon footprint and optimizing chemical recycling.
%3A%20Ratio%20of%20Short-Term%20Indebtedness%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_LSB_-_LakeShore-Biopharma-Co._-_Ratio-of-Short-Term-Indebtedness-to-Capital "YS Biopharma (LSB) - Short-Term Debt to Equity from 05/29/2024 to 10/04/2025 | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for ysbiopharm.com (LSB)
This metric determines the dependence of equity on liabilities with a maturity of up to one year, allowing for an assessment of liquidity and the risk of working capital deficits. By analyzing the current ratio of short-term debt to equity, an investor can evaluate the ability of LakeShore Biopharma Co. (LSB) to finance external research and raw material procurement without a critical debt load, which is essential given the high reliance on third-party CRO vendors.